| CASE REPORT |
|
| Year : 2019 | Volume
: 18
| Issue : 4 | Page : 437-439 |
|
|
Infliximab-induced hot kidneys on bone scintigraphy
Derya Cayir1, Mehmet Bozkurt1, Mustafa Filik2, Salih Sinan Gultekin1
1 Department of Nuclear Medicine, University of Health Sciences, Dişkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
2 Department of Nuclear Medicine, Ataturk University, Erzurum, Turkey
Correspondence Address:
Dr. Derya Cayir
Department of Nuclear Medicine, University of Health Sciences, Dişkapi Yildirim Beyazit Training and Research Hospital, Ankara 06110
Turkey
  | Check |
DOI: 10.4103/wjnm.WJNM_84_18 PMID: 31933566 
|
|
|
99mTechnetium-methylene diphosphonate bone scintigraphy is widely used in various clinical settings to detect bone abnormalities. Many reasons may cause abnormal tracer uptake in soft tissues on bone scintigraphy. Here, we present a 70-year-old man diagnosed with rheumatoid arthritis receiving chimeric anti-tumor necrosis factor alpha (TNF-α) therapy (infliximab). In order to evaluate the bone involvement of rheumatic disease, the patient underwent a whole-body bone scan that revealed left side dominant diffuse uptake in both kidneys defined as the “hot kidneys.” Since the patient had no other identifiable reason, anti-TNF-α therapy might be responsible for the “hot kidneys” on bone scan. Thus, therapy regiment of the patient changed from the chimeric anti-TNF-α to a human monoclonal TNF inhibitor (golimumab). After 6 months of the change of the therapy, the bone scintigraphy was repeated and revealed that the previous “hot kidneys” finding had disappeared.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 246 
